Skip to main content

Gadavist Side Effects

Generic name: gadobutrol

Medically reviewed by Drugs.com. Last updated on Jun 12, 2023.

Note: This document contains side effect information about gadobutrol. Some dosage forms listed on this page may not apply to the brand name Gadavist.

Applies to gadobutrol: intravenous solution.

Warning

Intravenous route (Solution)

Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) in patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. The risk for NSF is greatest in patients with acute kidney injury or chronic, severe kidney disease (GFR less than 30 mL/min/1.73 m(2). Evaluate patients for acute kidney injury or other conditions which may reduce renal function. Patients at risk for chronically reduced renal function (eg, age greater than 60 years, hypertension, or diabetes) should have their estimate the glomerular filtration rate (GFR) determined through laboratory testing. Do not exceed the recommended gadobutrol dose in patients at highest risk for NSF. Allow sufficient time for the drug to be eliminated by the body prior to subsequent doses.

Serious side effects of Gadavist

Along with its needed effects, gadobutrol (the active ingredient contained in Gadavist) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking gadobutrol:

Rare

Incidence not known

Other side effects of Gadavist

Some side effects of gadobutrol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Rare

For Healthcare Professionals

Applies to gadobutrol: intravenous solution.

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity/anaphylactoid reaction[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Dizziness, paresthesia, dysgeusia

Rare (less than 0.1%): Loss of consciousness, convulsion, parosmia[Ref]

Gastrointestinal

Common (1% to 10%): Nausea

Uncommon (0.1% to 1%): Vomiting

Rare (less than 0.1%): Dry mouth[Ref]

Dermatologic

Uncommon (0.1% to 1%): Rash, pruritus, erythema

Very rare (less than 0.01%): Face edema

Postmarketing reports: Nephrogenic systemic fibrosis[Ref]

Cardiovascular

Rare (less than 0.1%): Tachycardia, palpitation, pallor

Postmarketing reports: Cardiac arrest[Ref]

Respiratory

Respiratory side effects have included dyspnea.[Ref]

Local

Uncommon (0.1% to 1%): Injection site reactions[Ref]

Ocular

Very rare (less than 0.01%): Eyelid edema[Ref]

Other

Uncommon (0.1% to 1%): Feeling hot

Rare (less than 0.1%): Malaise, feeling cold[Ref]

General

The most common adverse reactions were headache, nausea, and dizziness.[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Gadavist (gadobutrol). Bayer Pharmaceutical Inc. 2011.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.